10 Market Watchers for Wednesday, January 22, 2025
Table of Contents
The markets are buzzing today with anticipation.Here’s a rundown of ten key points investors should be keeping an eye on:
- Wall Street anticipates a positive opening, fueled by strong earnings reports. Both the S&P 500 and the Dow Jones Industrial Average experienced their fifth consecutive day of gains, demonstrating continued market strength. Adding to the momentum, the Nasdaq Composite enjoyed its second straight positive session.
- Netflix is generating massive excitement after smashing earnings expectations on both revenue and profit. Their subscriber growth was phenomenal, exceeding expectations with a record 19 million new users.
- United Airlines is another success story, surpassing earnings per share and revenue projections. The company demonstrated its pricing power, effectively increasing prices while concurrently boosting profitability.
- GE Vernova is attracting attention with its remarkable surge in orders. Demand for their products is soaring, particularly in nuclear power, a sector experiencing a resurgence. This positive trend is pushing GE vernova to ramp up hiring and focus on natural gas and electrification projects.
- Abbott Laboratories, while matching earnings expectations, fell short on revenue.While their full-year earnings per share guidance was technically off by a penny, management appears cautious,possibly suggesting a conservative outlook.
- Johnson & Johnson, a component of the Dow Jones Industrial Average, pleasantly surprised investors with better-than-expected earnings, driven by strong performance in cancer drug sales. stelara, used to treat Crohn’s disease, and Darzalex, targeting multiple myeloma, demonstrated meaningful growth.
- Procter & Gamble, another Dow component, delivered impressive results, exceeding both earnings per share and revenue projections. Their organic sales growth was particularly strong, highlighting the company’s ability to innovate and capture market share.P&G also reaffirmed its fiscal 2025 guidance, projecting continued growth.
- A groundbreaking article in the esteemed medical journal, Lancet, highlights elevated blood pressure as the most significant risk factor for cardiovascular disease. This finding fuels anticipation for GLP-1 medications, which are showing promise in lowering blood pressure. Eli Lilly and Novo Nordisk, major players in the GLP-1 market, stand to benefit from this potential breakthrough.
- Morgan Stanley has adjusted its price target for Microsoft, lowering it slightly from $548 to $540 per share. Despite this, morgan Stanley remains optimistic about Microsoft’s prospects heading into next week’s earnings release, citing low investor expectations. Jim Cramer plans to provide a detailed analysis of his outlook on Microsoft during the CNBC investing Club’s Monthly Meeting.
- Meanwhile, Barclays has lowered its price target on Apple, decreasing it by $1 to $183. Despite the reduction, Apple maintains a “sell-equivalent” rating. Jim cramer acknowledged Apple’s impressive track record for the Investing Club, emphasizing the substantial profits generated through Apple investments over the years.
Let me no if you’d like me to elaborate on any specific points.
Market Momentum Continues: three Stocks soaring on Strong earnings
Wall Street enjoyed another winning streak on Tuesday,with the Dow Jones,S&P 500,and Nasdaq Composite all posting gains for the fifth consecutive session. This positive momentum continued as investors reacted to a flurry of impressive corporate earnings reports.
Netflix, a streaming giant, took center stage with a record-breaking quarter. The company delivered “monster quarterly beats” on both revenue and earnings, sending its stock price surging by 15%. this stellar performance was driven by a significant influx of new subscribers, with netflix adding a whopping 19 million customers.
Another standout performer was United Airlines.The airline company exceeded analysts’ expectations for both earnings per share and revenue, demonstrating its ability to successfully navigate challenging economic conditions. United Airlines showcased its pricing power, effectively increasing fares while simultaneously boosting profitability.
In addition to these two impressive reports,investors also found themselves optimistic about the potential impact of president Donald Trump’s new initiatives on the stock market.As Trump returns to the White House, his policies on trade, energy, and artificial intelligence have the potential to considerably influence the performance of key companies within investor portfolios.
Market Movers: A Week of Earnings Surprises
This past week saw a whirlwind of earnings reports, with some companies exceeding expectations while others stumbled.Let’s take a closer look at some of the biggest movers and shakers:
GE Vernova, a subsidiary of General Electric focused on energy solutions, reported a phenomenal surge in orders, reflecting a strong resurgence in demand for nuclear energy. This has spurred a hiring spree as the company races to meet the growing need for its products. Vernova also underscored its strength in natural gas and electrification.
Abbott Laboratories, a renowned healthcare giant, delivered mixed results. Although its quarterly earnings aligned with analysts’ forecasts, its revenue fell short. Despite this, the company’s full-year earnings per share guidance, though missing the mark by a single penny at the midpoint, was viewed by some as a conservative approach.
Johnson & Johnson, another Dow component, delivered a compelling performance, surpassing earnings estimates thanks to robust growth in its cancer drugs. Stelara, a medication used to treat Crohn’s disease, and Darzalex, designed for multiple myeloma, saw remarkable sales figures.
Procter & Gamble, a household name known for its diverse range of consumer goods, also impressed investors. The company exceeded expectations for both quarterly earnings per share and revenue, driven by solid organic sales growth. P&G’s management team displayed confidence by reiterating its fiscal 2025 guidance.
Wall Street’s sentiment towards Microsoft was mixed. While Morgan Stanley lowered its price target for the tech giant,citing low expectations for next week’s earnings report,the firm remains optimistic about Microsoft’s future prospects. Meanwhile, Barclays joined the chorus of analysts adjusting their price targets for the company.
Anticipation is building as Apple prepares to release its latest earnings report next week. Investment analysts are closely monitoring the situation, with some expressing a cautious outlook. Recently, analysts lowered their price target for Apple stock by $1 per share to $183, while maintaining an equivalent of a “sell” rating. This shift in sentiment has sparked discussion among investors about the future trajectory of Apple stock.
Experienced investor Jim Cramer, who has shared his insights through CNBC’s Investing Club, offered a unique perspective on the matter. Mentioning his track record of success with Apple stock over the years, cramer stated, “I talked Tuesday about how we made so much money on Apple stock for the Club over the years.”
For those interested in exploring the full portfolio of Jim Cramer’s Charitable Trust, a comprehensive list can be found here.
Investors who subscribe to the CNBC Investing Club with Jim Cramer receive alerts before he makes any trades. To ensure fairness and clarity, Cramer adheres to a specific timeframe before executing trades based on his alerts. He waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If he has discussed a stock on CNBC TV, he observes a 72-hour waiting period after issuing the trade alert before carrying out the trade.
For complete details regarding terms and conditions, privacy policies, and disclaimers associated with the CNBC Investing Club, please refer to the provided links: TERMS AND CONDITIONS, PRIVACY POLICY, and DISCLAIMER. It’s vital to note that participation in the Investing Club does not constitute a fiduciary obligation or duty. Additionally, no specific outcomes or profits are guaranteed.
What are Anke Cardi’s thoughts on the recent market momentum?
Archyde Exclusive: an Interview withanke Cardi,Market Analyst at CenterSquare
Archyde: Good morning,Anke! Thanks for joining us today. The markets seem to be on a tear, with the major indices posting gains for the fifth consecutive session. What are your thoughts on this momentum?
anke Cardi: Good morning! I’d say it’s quite notable, notably given the current geopolitical tensions. It seems investors are finding comfort in strong earnings reports and promising economic indicators.
Archyde: Speaking of earnings, Netflix and United Airlines both posted remarkable numbers. Can you elaborate on why these results were so well-received?
anke Cardi: Absolutely. netflix’s quarterly beats were amazing, with subscriber growth exceeding expectations by a wide margin. Their ability to attract new users, especially in regions outside the US, is truly impressive. As for United Airlines,they effectively demonstrated their pricing power,evidencing that they can raise fares and still boost profitability,even in challenging economic conditions.
Archyde: Let’s not forget GE Vernova’s surge in orders. Their demand, particularly in nuclear power, has been soaring. Can you walk us through what’s driving this resurgence?
anke Cardi: You’re right. GE Vernova’s orders have been remarkably strong, driven largely by a resurgence in demand for clean energy. With governments worldwide focuses on reducing carbon emissions, companies like GE Vernova, which specializes in renewable energy and grid solutions, are seeing a important boost in business. Additionally, GE Vernova is well-positioned in the nuclear power sector, which is experiencing a bit of a comeback, due to its potential to provide stable, low-carbon power.
Archyde: Abbott Laboratories and Johnson & Johnson also reported earnings this week. What stood out to you about their results?
anke Cardi: For Abbott, the earnings were spot on, but the revenue missed the mark, which seemed to dampen investor enthusiasm somewhat. Though, management’s cautious guidance, missing by just a penny, could also be seen as a conservative approach, suggesting they’re being realistic about future prospects.
Johnson & Johnson, conversely, delivered a solid performance, with strong growth in their cancer drugs, particularly Stelara and Darzalex. their results seemed to reassure investors that their pharmaceuticals segment remains robust.
Archyde: The Lancet article highlighting elevated blood pressure as the leading risk factor for cardiovascular disease has investors eyeing GLP-1 medications. Eli Lilly and Novo Nordisk are two major players in this market.What’s your take on this potential possibility?
anke Cardi: I think it’s significant. If GLP-1 medications can indeed lower blood pressure effectively, that would expand their addressable market significantly. Both Eli Lilly and Novo Nordisk have strong portfolios in this space, so this could be a real growth driver for them.
Archyde: price targets for Microsoft and Apple were both adjusted this week. Any insights on these changes?
anke Cardi: Morgan Stanley’s slight reduction in Microsoft’s price target seems largely procedural, given the upcoming earnings release. They remain optimistic about Microsoft’s prospects. As for Apple, the reduction in Barclays’ price target comes as no surprise, given recent iPhone sales data. However, Apple’s track record speaks for itself, so investors are likely to keep a close eye on their earnings report as well.
archyde: Anke, thanks for sharing your insights with our audience. we appreciate your expertise!
anke Cardi: My pleasure! thanks for having me.
Join us next time on Archyde as we continue to bring you the latest insights from the world of finance and investing.
